M&A | Shaping GCT Innovation
Wednesday, May 19, 2021
11:50 AM – 12:15 PM
The GCT M&A market is booming – many large pharmas have made at least one significant acquisition. How should we view the current GCT M&A market? What is its impact of the current M&A market on technology development? Are these M&A trends new are just another cycle? Has pharma strategy shifted and, if so, what does it mean for GCT companies? What does it mean for patients? What are the long-term prospects – can valuations hold up?
- Moderator:
-
- Adam Koppel, MD, PhD
-
- Managing Director, Bain Capital Life Sciences
- Speakers:
-
- Kenneth Custer, PhD
-
- Vice President, Business Development and Lilly New Ventures, Eli Lilly and Company
- Marianne De Backer, PhD
-
- Head of Strategy, Business Development & Licensing, and Member of the Executive Committee, Bayer
- Sean Nolan
-
- Board Chairman, Encoded Therapeutics & Affinia
- Executive Chairman, Jaguar Gene Therapy & Istari Oncology
-
Q&A
12:20 PM – 12:35 PM